Ruxolitinib cream for discoid lupus erythematosus: An open-label pilot study of 10 subjects - 14/12/24
Doi : 10.1016/j.jaad.2024.11.036
Alexandra M. Bender, MD, PhD a, Leah Laageide, MD a, Japsimran Kaur, MD b, Nicole Babkowski, BA c, Christopher T. Richardson, MD, PhD a, ⁎ 
a Dermatology, University of Rochester Medical Center, Rochester, New York
b University of Rochester School of Medicine and Dentistry, Rochester, New York
c University of Rochester, Rochester, New York
∗Correspondence to: Christopher T. Richardson, MD, PhD, Dermatology, University of Rochester Medical Center, 40 Celebration Dr, Rochester, NY 14642DermatologyUniversity of Rochester Medical Center40 Celebration DrRochesterNY14642
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Saturday 14 December 2024
Key words : clinical trial, cutaneous lupus erythematosus, discoid lupus erythematosus, Janus kinase inhibitor, lupus, ruxolitinib
| Funding sources: This study was supported by Incyte, Corp. REDCap support provided by Grant # UL1 TR002001 from the National Institutes of Health. |
|
| IRB approval status: Conducted under an investigational new drug application approved by the US Food and Drug Administration; IND 156455. Reviewed and approved by the University of Rochester Institutional Review Board; approval #6186. Clinicaltrials.gov: NCT04908280. |
|
| Prior presentation: This manuscript is not under consideration elsewhere and none of the contents have been previously published. |
© 2024
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?